SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies
Abstract The development of antibody responses to SARS-CoV-2 is an indicator of seroprevalence and may afford protection from infection. It has been presumed that antibody responses to SARS-CoV-2 will be impaired in patients with aggressive haematological malignancy (PHM) due to underlying immunological dysfunction caused by malignancy or systemic anti-cancer treatment (SACT), placing them at increased risk. Here we analysed longitudinal serum samples from ten hospitalised PHM with aggressive disease and on SACT, collected up to 103 days post-onset of COVID-19 symptoms. We found that the majority (8/9) of PHM with confirmed SARS-CoV-2 infection seroconverted and developed antibodies to the major SARS-CoV-2 antigens (S1 and N) with most (6/8) produced neutralising antibody responses. Furthermore, the dynamics of antibody responses were broadly similar to that reported for the general population, except for a possible delay to seroconversion. Our finding that PHM on SACT can make functional antibody responses to SARS-CoV-2 has important implications for patient management and serological monitoring of SARS-CoV-2 in high-risk groups..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 19. Okt. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O’Nions, J. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.09.29.20202846 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018861091 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018861091 | ||
| 003 | DE-627 | ||
| 005 | 20230429093303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201002s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.29.20202846 |2 doi | |
| 035 | |a (DE-627)XBI018861091 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.09.29.20202846 | ||
| 035 | |a (biorXiv)10.1101/2020.09.29.20202846 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a O’Nions, J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 antibody responses in patients with aggressive haematological malignancies |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The development of antibody responses to SARS-CoV-2 is an indicator of seroprevalence and may afford protection from infection. It has been presumed that antibody responses to SARS-CoV-2 will be impaired in patients with aggressive haematological malignancy (PHM) due to underlying immunological dysfunction caused by malignancy or systemic anti-cancer treatment (SACT), placing them at increased risk. Here we analysed longitudinal serum samples from ten hospitalised PHM with aggressive disease and on SACT, collected up to 103 days post-onset of COVID-19 symptoms. We found that the majority (8/9) of PHM with confirmed SARS-CoV-2 infection seroconverted and developed antibodies to the major SARS-CoV-2 antigens (S1 and N) with most (6/8) produced neutralising antibody responses. Furthermore, the dynamics of antibody responses were broadly similar to that reported for the general population, except for a possible delay to seroconversion. Our finding that PHM on SACT can make functional antibody responses to SARS-CoV-2 has important implications for patient management and serological monitoring of SARS-CoV-2 in high-risk groups. | ||
| 700 | 1 | |a Muir, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, J. |e verfasserin |4 aut | |
| 700 | 1 | |a Rees-Spear, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Earl, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Cherepanov, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, R. |e verfasserin |4 aut | |
| 700 | 1 | |a Khwaja, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Jolly, C. |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, L.E. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 19. Okt. |
| 773 | 1 | 8 | |g year:2020 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.29.20202846 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 19 |c 10 | ||
| 953 | |2 045F |a 570 | ||